Intolerance of dolutegravir-containing combination antiretroviral therapy: not just a pharmacokinetic drug interaction

    loading  Checking for direct PDF access through Ovid


de Boer and colleagues [1] have recently reported the results of a postmarketing, ‘real-life,’ observational study, documenting a rate of discontinuation of dolutegravir (mainly for neuropsychological events) much higher than those reported previously in randomized controlled trials. Remarkably, dolutegravir was stopped more frequently in patients treated with antiretroviral regimens which included abacavir. In view of that, the authors hypothesized that an interaction between dolutegravir and abacavir may have taken place as both drugs are metabolized by the same enzyme, UDP-glucuronosyltransferase.
    loading  Loading Related Articles